Cardiff Oncology, Inc. (CRDF) — Financial statements
Income statement, balance sheet, and cash flow for Cardiff Oncology, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.59↓13.2% | 0.68↑40.0% | 0.49↑26.4% | 0.39↑7.5% | 0.36 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.59↓13.2% | 0.68↑40.0% | 0.49↑26.4% | 0.39↑7.5% | 0.36 | |
| Operating Expenses | ||||||
| R&D Expenses | 35↓4.1% | 37↑12.2% | 33↑21.2% | 27↑56.0% | 17 | |
| General & Administrative Expenses | 14↑14.0% | 12↓4.3% | 13↓1.0% | 13↑11.3% | 12 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 14↑14.0% | 12↓4.3% | 13↓1.0% | 13↑11.3% | 12 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 50↑0.4% | 49↑7.5% | 46↑13.9% | 40↑37.9% | 29 | |
| Total Costs & Expenses | 50↑0.4% | 49↑7.5% | 46↑13.9% | 40↑37.9% | 29 | |
| Operating Results | ||||||
| Operating Income | -49↓0.6% | -49↓7.1% | -45↓13.8% | -40↓38.3% | -29 | |
| Depreciation & Amortization | 0.90↑123.8% | 0.40↑1.5% | 0.40↑68.6% | 0.24↓47.7% | 0.45 | |
| EBITDA | -48↑0.4% | -48↓7.2% | -45↓13.5% | -40↓39.6% | -28 | |
| EBIT | -49↓0.6% | -49↓7.1% | -45↓13.8% | -40↓38.3% | -29 | |
| Interest & Other Income | ||||||
| Net Interest Income | 3↓4.8% | 3↓19.9% | 4↑157.4% | 2↑498.9% | 0.26 | |
| Interest Income | 3↓4.8% | 3↓19.9% | 4↑157.4% | 2↑498.9% | 0.26 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 3↓3.4% | 3↓18.9% | 4↑231.5% | 1↑112.4% | 0.56 | |
| Income Before Tax | -46↓0.9% | -45↓9.6% | -41↓7.1% | -39↓36.8% | -28 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -46↓0.9% | -45↓9.6% | -41↓7.1% | -39↓36.8% | -28 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -46↓0.9% | -45↓9.6% | -41↓7.1% | -39↓36.8% | -28 | |
| Bottom-Line Net Income | -46↓0.9% | -45↓9.6% | -41↓7.1% | -39↓36.8% | -28 | |
| EPS (Basic) | -0.69↑27.4% | -0.95↓2.2% | -0.93↓4.5% | -0.89↓21.9% | -0.73 | |
| EPS (Diluted) | -0.69↑27.4% | -0.95↓2.2% | -0.93↓4.5% | -0.89↓21.9% | -0.73 | |
| Weighted Average Shares | 67↑40.3% | 48↑6.7% | 45↑2.5% | 44↑11.7% | 39 | |
| Weighted Average Diluted Shares | 67↑40.3% | 48↑6.7% | 45↑2.5% | 44↑11.7% | 39 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.